Preclinical Rationale for Targeting the PD-1/PD-L1 Axis in Combination with a CD38 Antibody in Multiple Myeloma and Other CD38-Positive Malignancies
The CD38-targeting antibody daratumumab mediates its anti-myeloma activities not only through Fc-receptor-dependent effector mechanisms, but also by its effects on T-cell immunity through depletion of CD38<sup>+</sup> regulatory T-cells, regulatory B-cells, and myeloid-derived suppressor...
Main Authors: | , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-12-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/12/12/3713 |
id |
doaj-5845266de4584bbb92485488093b8aa0 |
---|---|
record_format |
Article |
spelling |
doaj-5845266de4584bbb92485488093b8aa02020-12-11T00:04:31ZengMDPI AGCancers2072-66942020-12-01123713371310.3390/cancers12123713Preclinical Rationale for Targeting the PD-1/PD-L1 Axis in Combination with a CD38 Antibody in Multiple Myeloma and Other CD38-Positive MalignanciesChristie P. M. Verkleij0Amy Jhatakia1Marloes E. C. Broekmans2Kristine A. Frerichs3Sonja Zweegman4Tuna Mutis5Natalie A. Bezman6Niels W. C. J. van de Donk7Department of Hematology, Cancer Center Amsterdam, Amsterdam University Medical Center, Vrije Universiteit Amsterdam, 1081 HV Amsterdam, The NetherlandsBristol-Myers Squibb, Redwood City, CA 94063, USADepartment of Hematology, Cancer Center Amsterdam, Amsterdam University Medical Center, Vrije Universiteit Amsterdam, 1081 HV Amsterdam, The NetherlandsDepartment of Hematology, Cancer Center Amsterdam, Amsterdam University Medical Center, Vrije Universiteit Amsterdam, 1081 HV Amsterdam, The NetherlandsDepartment of Hematology, Cancer Center Amsterdam, Amsterdam University Medical Center, Vrije Universiteit Amsterdam, 1081 HV Amsterdam, The NetherlandsDepartment of Hematology, Cancer Center Amsterdam, Amsterdam University Medical Center, Vrije Universiteit Amsterdam, 1081 HV Amsterdam, The NetherlandsBristol-Myers Squibb, Redwood City, CA 94063, USADepartment of Hematology, Cancer Center Amsterdam, Amsterdam University Medical Center, Vrije Universiteit Amsterdam, 1081 HV Amsterdam, The NetherlandsThe CD38-targeting antibody daratumumab mediates its anti-myeloma activities not only through Fc-receptor-dependent effector mechanisms, but also by its effects on T-cell immunity through depletion of CD38<sup>+</sup> regulatory T-cells, regulatory B-cells, and myeloid-derived suppressor cells. Therefore, combining daratumumab with modulators of other potent immune inhibitory pathways, such as the PD-1/PD-L1 axis, may further improve its efficacy. We show that multiple myeloma (MM) cells from relapsed/refractory patients have increased expression of PD-L1, compared to newly diagnosed patients. Furthermore, PD-1 is upregulated on T-cells from both newly diagnosed and relapsed/refractory MM patients, compared to healthy controls. In short-term experiments with bone marrow samples from MM patients, daratumumab-mediated lysis was mainly associated with the MM cells’ CD38 expression levels and the effector (NK-cells/monocytes/T-cells)-to-target ratio, but not with the PD-L1 expression levels or PD-1<sup>+</sup> T-cell frequencies. Although PD-1 blockade with nivolumab did not affect MM cell viability or enhanced daratumumab-mediated lysis in short-term ex vivo experiments, nivolumab resulted in a mild but clear increase in T-cell numbers. Moreover, with a longer treatment duration, PD-1 blockade markedly improved anti-CD38 antibody-mediated cytotoxicity in vivo in murine CD38<sup>+</sup> tumor models. In conclusion, dual targeting of CD38 and PD-1 may represent a promising strategy for treating MM and other CD38-positive malignancies.https://www.mdpi.com/2072-6694/12/12/3713immunotherapymultiple myelomatumor microenvironmentPD-1PD-L1CD38 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Christie P. M. Verkleij Amy Jhatakia Marloes E. C. Broekmans Kristine A. Frerichs Sonja Zweegman Tuna Mutis Natalie A. Bezman Niels W. C. J. van de Donk |
spellingShingle |
Christie P. M. Verkleij Amy Jhatakia Marloes E. C. Broekmans Kristine A. Frerichs Sonja Zweegman Tuna Mutis Natalie A. Bezman Niels W. C. J. van de Donk Preclinical Rationale for Targeting the PD-1/PD-L1 Axis in Combination with a CD38 Antibody in Multiple Myeloma and Other CD38-Positive Malignancies Cancers immunotherapy multiple myeloma tumor microenvironment PD-1 PD-L1 CD38 |
author_facet |
Christie P. M. Verkleij Amy Jhatakia Marloes E. C. Broekmans Kristine A. Frerichs Sonja Zweegman Tuna Mutis Natalie A. Bezman Niels W. C. J. van de Donk |
author_sort |
Christie P. M. Verkleij |
title |
Preclinical Rationale for Targeting the PD-1/PD-L1 Axis in Combination with a CD38 Antibody in Multiple Myeloma and Other CD38-Positive Malignancies |
title_short |
Preclinical Rationale for Targeting the PD-1/PD-L1 Axis in Combination with a CD38 Antibody in Multiple Myeloma and Other CD38-Positive Malignancies |
title_full |
Preclinical Rationale for Targeting the PD-1/PD-L1 Axis in Combination with a CD38 Antibody in Multiple Myeloma and Other CD38-Positive Malignancies |
title_fullStr |
Preclinical Rationale for Targeting the PD-1/PD-L1 Axis in Combination with a CD38 Antibody in Multiple Myeloma and Other CD38-Positive Malignancies |
title_full_unstemmed |
Preclinical Rationale for Targeting the PD-1/PD-L1 Axis in Combination with a CD38 Antibody in Multiple Myeloma and Other CD38-Positive Malignancies |
title_sort |
preclinical rationale for targeting the pd-1/pd-l1 axis in combination with a cd38 antibody in multiple myeloma and other cd38-positive malignancies |
publisher |
MDPI AG |
series |
Cancers |
issn |
2072-6694 |
publishDate |
2020-12-01 |
description |
The CD38-targeting antibody daratumumab mediates its anti-myeloma activities not only through Fc-receptor-dependent effector mechanisms, but also by its effects on T-cell immunity through depletion of CD38<sup>+</sup> regulatory T-cells, regulatory B-cells, and myeloid-derived suppressor cells. Therefore, combining daratumumab with modulators of other potent immune inhibitory pathways, such as the PD-1/PD-L1 axis, may further improve its efficacy. We show that multiple myeloma (MM) cells from relapsed/refractory patients have increased expression of PD-L1, compared to newly diagnosed patients. Furthermore, PD-1 is upregulated on T-cells from both newly diagnosed and relapsed/refractory MM patients, compared to healthy controls. In short-term experiments with bone marrow samples from MM patients, daratumumab-mediated lysis was mainly associated with the MM cells’ CD38 expression levels and the effector (NK-cells/monocytes/T-cells)-to-target ratio, but not with the PD-L1 expression levels or PD-1<sup>+</sup> T-cell frequencies. Although PD-1 blockade with nivolumab did not affect MM cell viability or enhanced daratumumab-mediated lysis in short-term ex vivo experiments, nivolumab resulted in a mild but clear increase in T-cell numbers. Moreover, with a longer treatment duration, PD-1 blockade markedly improved anti-CD38 antibody-mediated cytotoxicity in vivo in murine CD38<sup>+</sup> tumor models. In conclusion, dual targeting of CD38 and PD-1 may represent a promising strategy for treating MM and other CD38-positive malignancies. |
topic |
immunotherapy multiple myeloma tumor microenvironment PD-1 PD-L1 CD38 |
url |
https://www.mdpi.com/2072-6694/12/12/3713 |
work_keys_str_mv |
AT christiepmverkleij preclinicalrationalefortargetingthepd1pdl1axisincombinationwithacd38antibodyinmultiplemyelomaandothercd38positivemalignancies AT amyjhatakia preclinicalrationalefortargetingthepd1pdl1axisincombinationwithacd38antibodyinmultiplemyelomaandothercd38positivemalignancies AT marloesecbroekmans preclinicalrationalefortargetingthepd1pdl1axisincombinationwithacd38antibodyinmultiplemyelomaandothercd38positivemalignancies AT kristineafrerichs preclinicalrationalefortargetingthepd1pdl1axisincombinationwithacd38antibodyinmultiplemyelomaandothercd38positivemalignancies AT sonjazweegman preclinicalrationalefortargetingthepd1pdl1axisincombinationwithacd38antibodyinmultiplemyelomaandothercd38positivemalignancies AT tunamutis preclinicalrationalefortargetingthepd1pdl1axisincombinationwithacd38antibodyinmultiplemyelomaandothercd38positivemalignancies AT natalieabezman preclinicalrationalefortargetingthepd1pdl1axisincombinationwithacd38antibodyinmultiplemyelomaandothercd38positivemalignancies AT nielswcjvandedonk preclinicalrationalefortargetingthepd1pdl1axisincombinationwithacd38antibodyinmultiplemyelomaandothercd38positivemalignancies |
_version_ |
1724387013295079424 |